Guanidines (i.e., N=c(-n)-n) Patents (Class 514/634)
-
Publication number: 20100234232Abstract: This invention provides an emulsion composition, containing a component (A) which is at least one selected from the group consisting of alkanol having 6 to 20 carbon atoms, alkenol having 6 to 20 carbons, polyoxyethylene alkyl ester, polyoxyethylene alkyl diester, polyoxyethylene alkenyl ester, polyoxyethylene dialkenyl ester, polyoxyethylene.polyoxypropylene.block copolymer and a silicon-based surfactant, a component (B) which is at least one polyoxyalkylene aryl phenyl ether, and a component (C) which is an aromatic hydrocarbon-based nonpolar solvent, wherein the emulsion composition contains neither anionic surfactant nor cationic surfactant, and an agrochemical emulsion composition using the emulsion composition.Type: ApplicationFiled: November 11, 2008Publication date: September 16, 2010Applicant: NIPPON SODA CO., LTD.Inventors: Hiroshi Dairiki, Tetsutaro Kai
-
Publication number: 20100222433Abstract: A disinfectant cleaner is provided by combining an alkyl dimethyl benzyl ammonium chloride, an octyl decyl dimethyl ammonium chloride, a dioctyl dimethyl ammonium chloride, a didecyl dimethyl ammonium chloride, an alkylamine, a guanidine, a penetrant, a surfactant, a chelant, an essence and deionized water.Type: ApplicationFiled: March 1, 2010Publication date: September 2, 2010Inventors: Jialu Xue, Yinping Ren, Yue Wang, Xiaoping Ren, Zhonghua Xue, Jinhua Ren
-
Patent number: 7772284Abstract: An inexpensive, easily available, and convenient method of treating or preventing a virus infection is provided. The present invention relates to a method for the treatment or prevention of virus infections using polybiguanide-based compounds administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof. The invention relies on the unique biochemical reaction in which polybiguanide-based compounds interfere with the spread of virus within or between organisms. The compositions and formulations described in the present invention are effective means to reduce the infectivity of the human immunodeficiency virus type 1 (HIV-1), and human herpes simplex viruses, and also to kill the causative organisms of many other sexually transmitted diseases (STDs).Type: GrantFiled: August 27, 2003Date of Patent: August 10, 2010Inventors: Mohamed E. Labib, Richard F. Stockel
-
Patent number: 7767654Abstract: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described.Type: GrantFiled: May 27, 2005Date of Patent: August 3, 2010Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventor: Kirk W. Johnson
-
Publication number: 20100190766Abstract: Antibacterial compounds of formula (I) are provided: as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.Type: ApplicationFiled: December 10, 2009Publication date: July 29, 2010Applicant: Achaogen, Inc.Inventors: Heinz E. Moser, Qing Lu, Phillip A. Patten, Dan Wang, Ramesh Kasar, Stephen Kaldor, Brian D. Patterson
-
Publication number: 20100173996Abstract: Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides.Type: ApplicationFiled: February 9, 2010Publication date: July 8, 2010Inventors: Paul E. Carlson, H. Edwin Nehus, Jodi L. Martin
-
Publication number: 20100172890Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.Type: ApplicationFiled: February 1, 2010Publication date: July 8, 2010Inventors: Gad Gilad, Varda Gilad
-
Patent number: 7745392Abstract: Disclosed herein are guanidinium containing compounds consisting of a core moiety with a plurality of side chains containing guanidinium groups. Such compounds have enhanced translocation across cellular membranes and epithelial tissues. The compounds may also have a therapeutic or other biologically active moiety attached so that these moieties may be effectively transported into a cell by the guanidinium containing compound.Type: GrantFiled: September 21, 2006Date of Patent: June 29, 2010Assignee: Nitto Denko CorporationInventors: Zheng Hou, Jian Liu, Lei Yu
-
Publication number: 20100158857Abstract: The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods.Type: ApplicationFiled: May 23, 2007Publication date: June 24, 2010Inventors: Wolfram Samlowski, Muralidhar Kondapaneni, John McGregor
-
Publication number: 20100160445Abstract: Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides.Type: ApplicationFiled: July 19, 2007Publication date: June 24, 2010Inventors: Paul E. Carlson, H. Edwin Nehus, Jodi L. Martin
-
Patent number: 7727979Abstract: The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R?)— or —O— and R? is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence.Type: GrantFiled: March 22, 2004Date of Patent: June 1, 2010Assignee: Actelion Pharmaceuticals Ltd.Inventors: Eva Caroff, Matthias Steger, Oliver Valdenaire, Anja Fecher, Volker Breu, Kurt Hilpert, Heinz Fretz, Thomas Giller
-
Publication number: 20100130495Abstract: The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases.Type: ApplicationFiled: November 6, 2009Publication date: May 27, 2010Applicant: ASTRAZENECA ABInventors: Rickard FORSBLOM, Kim PAULSEN, Didier ROTTICCI, Ellen SANTANGELO, Magnus WALDMAN
-
Publication number: 20100104628Abstract: The present invention relates, in general, to neuroblastoma and, in particular, to a method of treating neuroblastoma tumors, including refractory neuroblastoma tumors. The invention also relates to compounds and compositions suitable for use in such a method.Type: ApplicationFiled: March 28, 2008Publication date: April 29, 2010Applicant: Duke UniversityInventors: Susan M. Ludeman, Michael P. Gamcsik, Timothy A. Driscoll, James B. Springer, O. Michael Colvin, David J. Adams, Karel Base
-
Publication number: 20100092469Abstract: The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCca-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and/or TRPM4 antagonists that inhibit the NCca-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and/or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and/or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example.Type: ApplicationFiled: February 8, 2008Publication date: April 15, 2010Inventors: J. Marc Simard, Vladimir Gerzanich
-
Publication number: 20100056641Abstract: There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0, 1, 2 or 3, saturated or unsaturated; most preferably at least one of R1 to R5 represents halogen; at least one of R1, R2, R3, R4 and R5 is selected from —S—R or —COOR, or two or more Of R1-R5 comprise a linking group such as —S—(CH2)mS—, where m is 1, 2 or 3 and R is selected from alkyl having 1 to 5 carbon atoms, cycloalkyl having 3-6 carbon atoms, hydroxy, and aryl having 6 to 10 carbon atoms, such groups being optionally substituted, and when R1 is selected from —S—R, then at least one of R2, R3 and R5 is most preferably selected from halogen; and R1, R2, R3, R4 and R5 are otherwise the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and pharmacologically acceptable salType: ApplicationFiled: December 13, 2007Publication date: March 4, 2010Applicant: ACURE PHARMA ABInventors: Torbjorn Lundstedt, Elisabeth Seifert, Per Lek, Arne Boman
-
Publication number: 20100015250Abstract: An aqueous hydraulic fluid composition comprising of one or more lubricants such as a monovalent metal salt, ammonium, or alkanolamine salt of a dicarboxylic acid, such as a C21 dicarboxylic acid is described in which the aqueous hydraulic fluid composition demonstrates increased thermal stability when exposed to elevated temperatures for a prolonged period of time while being able to tolerate the presence of 10% v/v synthetic seawater. The aqueous hydraulic fluid composition contains less than about 20% by weight (preferably none or substantially none) of an oil selected from the group consisting of mineral oils, synthetic hydrocarbon oils, and mixtures thereof.Type: ApplicationFiled: July 15, 2008Publication date: January 21, 2010Inventor: Ian D. Smith
-
Publication number: 20090280069Abstract: Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro-organisms. For example, when applied topically, proguanil is particularly effective against Propionibacterium acnes, a bacteria that causes acne; Corynebacterium minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a bacteria that causes vaginosis; Trichomonas vaginalis, a protozoan that causes trichomoniasis and C. albicans, a fungus (a form of yeast).Type: ApplicationFiled: May 8, 2009Publication date: November 12, 2009Applicant: Tolmar, Inc.Inventor: Kenneth C. Godowski
-
Publication number: 20090275663Abstract: The invention relates to medicine, in particular to sanitary and hygiene, more specifically to methods for producing a disinfecting agent for decontaminating different types of water, including drinking water. The inventive disinfecting agent producing method by dissolving quaternary ammonium compounds in water in the presence of an active additive in the form of guanidines, consists in preparing an aqueous 1-15% guanidine solution by permanently agitating it at a temperature ranging from 30 to 90° C., in cooling the solution accompanied with a precipitation control, when the precipitation process is over, in filtering the solution by using a filter whose cell size ranges from 10 to 1 mkm and in adding the quaternary ammonium compounds into the solution in such away that the concentration thereof in said solution is equal to 0.1-3%.Type: ApplicationFiled: November 14, 2005Publication date: November 5, 2009Inventors: Sergei Alexeevich Balekhov, Valery Mikhailovich Nikolaev, Alexei Semenovich Scherba
-
Patent number: 7608250Abstract: A cosmetic composition for skin and/or hair, which comprises at least one kind of substance selected from the group consisting of an N?,NG-di-acylarginine, for example, a compound represented by the following general formula (I): wherein R1 and R2 each independently represents a straight or branched-chain alkyl group having 1 to 21 carbon atoms or a straight or branched-chain alkenyl group having 2 to 21 carbon atoms. The cosmetic composition imparts much moistness and superior conditioning effects such as body or elasticity to hair, and to skin, said composition does not impart tackiness and blocked feeling, whilst imparts superior feeling of use such as moistness.Type: GrantFiled: October 6, 2005Date of Patent: October 27, 2009Assignee: Ajinomoto Co., Inc.Inventors: Naoya Yamato, Ryosuke Yumioka
-
Patent number: 7582656Abstract: Compounds of the formula (I): in which the radicals R and R1 to R10 are as defined in the description, processes for the preparation of them, use thereof for the treatment of cardiovascular diseases, and pharmaceutical compositions comprising them.Type: GrantFiled: June 28, 2005Date of Patent: September 1, 2009Assignee: Merck Patent GesellschaftInventors: Didier Roche, Bruno Roux, Isabelle Berard
-
Publication number: 20090169608Abstract: Topical composition for use especially as a skin lightener, characterized in that it contains an effective amount of at least one compound of general formula (I) or a mixture of such compounds and/or an acid addition salt thereof: in which X is NH or a direct bond and n is 2, 3 or 4, preferably 2 or 3, and its use for lightening skin colour, for depigmenting liver spots and for evening out non-uniformities in skin colouration. The invention further relates to dermatologically effective compositions containing at least one disulfide of general formula (I) and at least one additional skin care ingredient.Type: ApplicationFiled: October 9, 2006Publication date: July 2, 2009Applicant: DSM IP ASSETS B.V.Inventors: Hugo Ziegler, Peter Wikstroem, Martin Stockli
-
Patent number: 7528173Abstract: Compounds of the following formula (I), for example: (1), wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.Type: GrantFiled: March 21, 2003Date of Patent: May 5, 2009Assignee: Schering AktiengesellshaftInventors: Brad Buckman, Kumar Emayan, Imadul Islam, Karen May, Judi Bryant, Raju Mohan, Christopher West, Shendong Yuan
-
Patent number: 7521479Abstract: The invention is related to the treatment of prion-related diseases such as the transmissible spongiform encephalopathies (TSEs) in mammals by administering chaotropic agents to or inducing a hyperthermia state in the affected mammals.Type: GrantFiled: April 16, 2001Date of Patent: April 21, 2009Assignees: Panacea Pharmaceuticals, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Carl R. Merril, Hossein A. Ghanbari
-
Publication number: 20090099239Abstract: The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.Type: ApplicationFiled: June 23, 2006Publication date: April 16, 2009Inventors: Gary Dinneen Ewart, Wayne Morris Best
-
Publication number: 20090076110Abstract: An Amino Acid Compound is described. The Amino Acid Compound may comprise an Amino Acid and one of a Nitrate and a Nitrite. The Amino Acid may be one of Agmatine, Arginine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine.Type: ApplicationFiled: December 4, 2007Publication date: March 19, 2009Inventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20090069435Abstract: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an topical surface and/or an otic surface of an animal (e.g., canine, feline) such that an topical malady and/or otic malady may be inhibited and/or ameliorated.Type: ApplicationFiled: August 11, 2008Publication date: March 12, 2009Inventor: Jeffery A. Whiteford
-
Publication number: 20090061031Abstract: The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPAR?2, LPL and ?P2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual.Type: ApplicationFiled: July 9, 2007Publication date: March 5, 2009Inventors: Sylvia Lee-Huang, Paul L. Huang, Philip Lin Huang, Dawei Zhang, John Z.H. Zhang, Young Tae Chang, Jae Wook Lee, Ju Bao, Yongtao Sun
-
Publication number: 20090054528Abstract: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of an animal (e.g., canine, feline) such that an oral malady may be inhibited and/or ameliorated.Type: ApplicationFiled: August 11, 2008Publication date: February 26, 2009Inventor: Jeffery A. Whiteford
-
Publication number: 20090036462Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.Type: ApplicationFiled: July 15, 2005Publication date: February 5, 2009Applicant: Onconova Therapeutics, Inc.Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
-
Publication number: 20080305186Abstract: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.Type: ApplicationFiled: June 11, 2007Publication date: December 11, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Harold R. Garner, Mounir Errami
-
Publication number: 20080300164Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: ApplicationFiled: October 4, 2005Publication date: December 4, 2008Applicant: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
-
Publication number: 20080293751Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.Type: ApplicationFiled: November 15, 2007Publication date: November 27, 2008Inventors: Robert Greenhouse, Ralph New Harris, III, Saul Jaime-Figueroa, James M. Kress, David Bruce Repke, Russell Stephen Stabler
-
Publication number: 20080272062Abstract: Devices and methods for inactivating microbiological contaminants in a fluid are provided for use in water, air, and other fluid treatment applications. The device includes (i) a housing having at least one fluid inlet and at least one fluid outlet; and (ii) an antimicrobial material secured in the housing between said at least one fluid inlet and said at least one fluid outlet. In one embodiment, the antimicrobial material is a biguanide dihydrate compound, such as a chlorhexidine dihydrate, which exhibits broad spectrum antimicrobial activity.Type: ApplicationFiled: July 10, 2008Publication date: November 6, 2008Applicant: WATER VISIONS INTERNATIONAL, INC.Inventors: Jan W. Gooch, Arthur W. Johnston, Arthur F. Johnston
-
Publication number: 20080260716Abstract: Methods and compositions for high level disinfection (as herein defined) of a surface. Methods include treating the surface with a composition including a quaternary ammonium compound in a concentration which exceeds 1% w/w and the temperature of treatment is in the range of from 30° C. to 80° C. A log (6) reduction in Mycobacterium terrae is achieved on the surface in less than 10 minutes. The temperature may be produced by a physical chaotrope, a chemical chaotrope (such as) boron or a boron compound or complex or a combination of chaotropic agents. Sequestering agents and enzymes maybe added.Type: ApplicationFiled: July 5, 2005Publication date: October 23, 2008Applicant: Nanosonics Pty LimitedInventors: Steven Kritzler, Alex Sava
-
Publication number: 20080255230Abstract: Disclosed herein is compound having a formula as described herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: March 28, 2008Publication date: October 16, 2008Inventors: Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
-
Patent number: 7432397Abstract: The invention relates to compounds of formula: (I) or a salt or solvate thereof, wherein: R1 is —11CH2R5 or [18F]—C1-4 fluoroalkyl wherein R5 is hydrogen or C1-4 alkyl; R2 is hydrogen or C1-4 alkyl; R3 is halo; and R4 is halo, C1-4 alkylthio, or C1-4 alkyl; and their use for imaging central nervous system (CNS) receptors.Type: GrantFiled: July 16, 2003Date of Patent: October 7, 2008Assignee: Hammersmith Imanet Ltd.Inventors: Frank Brady, Sajinder Kaur Luthra
-
Publication number: 20080207581Abstract: A coating system and method are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two of the cyclic groups may include quaternary ammonium moieties. In some embodiments, a method may include applying a coating to a surface. The coating may be antimicrobial. A coating may include antimicrobial bridged polycyclic compounds. Bridged polycyclic compounds may include quaternary ammonium compounds. Bridged polycyclic compounds based coating systems may impart self-cleaning properties to a surface.Type: ApplicationFiled: May 2, 2007Publication date: August 28, 2008Inventors: Jeffery A. Whiteford, William P. Freeman
-
Publication number: 20080200553Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.Type: ApplicationFiled: April 14, 2008Publication date: August 21, 2008Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventor: Heinz-Werner KLEEMANN
-
Publication number: 20080188505Abstract: The present invention relates to a topical skin care composition containing a safe and effective amount of a skin care active comprising agmatine, and its salt; a safe and effective amount of a first additional skin care active selected from the group consisting of BHT or BHA, hexamidine, cetyl pyridinium chloride, green tea catechins, phytosterols, ursolic acid, compounds derived from plant extracts, their salts and derivatives; and a dermatologically acceptable carrier for the agmatine composition. The present invention also relates to methods of using such agmatine compositions to regulate hair growth and the condition of mammalian skin. Said methods generally comprise the step of topically applying the composition to the skin of a mammal needing such treatment, a safe and effective amount of such compositions.Type: ApplicationFiled: March 27, 2008Publication date: August 7, 2008Inventors: John Erich Oblong, Sara Johnson McPhail, Shannon Christine McArthur, Charles Carson Bascom, David Joseph Eickhoff, John McMillan McIver
-
Publication number: 20080182884Abstract: The invention relates to a method of using fungicides for protecting peanut plants, which comprises applying to the field a composition comprising dodecylguanidine as active ingredient, and such compositions useful for treating peanuts crops against early leaf spot and late leaf spot.Type: ApplicationFiled: January 31, 2007Publication date: July 31, 2008Inventor: Laurent Cornette
-
Publication number: 20080146673Abstract: Pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.Type: ApplicationFiled: January 11, 2008Publication date: June 19, 2008Applicant: sanofi-aventis Deutschland GmbHInventor: Heinz-Werner KLEEMANN
-
Patent number: 7368605Abstract: Formula (I) compounds are described where the groups are as identified in the text, and their use as medicines, particularly as anti-diabetes, serum glucose-lowering and anti-obesity agents. They are useful for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, and its complications, syndrome X, the various forms of insulin resistance, and hyperlipidaemias, as well as for the treatment of obesity.Type: GrantFiled: December 1, 2003Date of Patent: May 6, 2008Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Fabio Giannessi, Emanuela Tassoni, Maria Ornella Tinti, Pompeo Pessotto, Maurizio Botta, Pederico Corelli
-
Patent number: 7351743Abstract: The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.Type: GrantFiled: August 11, 2000Date of Patent: April 1, 2008Assignee: WyethInventors: Stanley M. Goldin, James B. Fischer, Andrew Gannett Knapp, N. Laxma Reddy, David Berlove, Graham J. Durant, Subbarao Katragadda, Lain-Yen Hu, Sharad Magar, Wenhong Fan, Elizabeth Yost, Juo Qing Guo
-
Patent number: 7335639Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.Type: GrantFiled: August 2, 2005Date of Patent: February 26, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Bret A. Shirley, Maninder S. Hora
-
Patent number: 7322369Abstract: Methods of detaching microorganisms (e.g., bacteria) from, or of inhibiting microbial (e.g., bacterial) attachment to, animal or poultry carcasses or seafood or parts thereof, wherein the method involves contacting animal or poultry carcasses or seafood or parts thereof at least once with at least one of the following: (i) a polysulfated polysaccharide, (ii) carboxymethyl cellulose, or (iii) guanidine or arginine, optionally together with sodium chloride and at least one non-ionic surfactant, or (iv) mixtures thereof, in an amount effective to detach microorganisms (e.g., bacteria) from, or inhibit microbial (e.g., bacterial) attachment to, animal or poultry carcasses or seafood or parts thereof.Type: GrantFiled: October 6, 2004Date of Patent: January 29, 2008Assignee: The United States of America as Represented by the Secretary of AgricultureInventor: Marjorie B. Medina
-
Patent number: 7285682Abstract: The present invention provides terphenyl guanidine compounds of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.Type: GrantFiled: February 13, 2006Date of Patent: October 23, 2007Assignee: WyethInventor: Baihua Hu
-
Patent number: 7262222Abstract: Ortho phenylphenol or its sodium salt is shown to form synergistic antimicrobial mixtures with nitrogen and aldehyde-containing microbiocides.Type: GrantFiled: January 16, 2003Date of Patent: August 28, 2007Assignee: Verichem, Inc.Inventors: Paul E. Carlson, H. Edwin Nehus
-
Patent number: 7262168Abstract: Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures.Type: GrantFiled: September 19, 2005Date of Patent: August 28, 2007Assignee: Chiron CorporationInventors: Bret A. Shirley, Kamaljit Bajwa
-
Patent number: 7229961Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length (SEQ ID NO:86).Type: GrantFiled: February 25, 2002Date of Patent: June 12, 2007Assignee: Cellgate, Inc.Inventors: Jonathan B. Rothbard, Paul A. Wender, P. Leo McGrane, Lalitha V. S. Sista, Thorsten A. Kirschberg
-
Patent number: 7208521Abstract: The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.Type: GrantFiled: February 16, 2005Date of Patent: April 24, 2007Assignee: Wilex AGInventors: Viktor Magdolen, Luis Moroder, Stefan Sperl, Jörg Stürzebecher, Olaf Wilhelm